A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion

This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).

开始日期2023-12-18

申办/合作机构

SciTech Development LLC

NCT06181760 / Completed临床1期

A Phase 1a, Randomized, Double-blind Placebo-controlled Study to Evaluate Safety and Tolerability and to Characterize the Pharmacokinetic Profile of Single Ascending Doses of Fenretinide Oral Capsules in Healthy Adult Volunteers

The goal of this clinical trial is to learn about a single dose of fenretinide in healthy volunteers, in both a fasted and fed state. The main questions it aims to answer are: •How well is a single dose of fenretinide tolerated? AND •How is a single dose of fenretinide metabolized in healthy volunteers?
Participants will be asked to:
Remain confined in a clinical research unit for 5 days after dosing.
Provide blood samples for intense PK sampling and safety labs.
Fast for 10 hours prior to administration of study drug (fasted cohorts).
Consume a high fat meal prior to administration of study drug (fed cohort).
Return to the clinic for a single follow-up visit for safety assessments. Researchers will compare active fenretinide to placebo to see if fenretinide is more or less tolerable than placebo.

开始日期2023-11-22

申办/合作机构

Island Pharmaceuticals Ltd.

NCT05999435 / Active, not recruiting临床2/3期

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, ADAPTIVE PHASE 2/3 STUDY OF THE EFFICACY OF LAU-7b IN THE TREATMENT OF ADULTS WITH LONG COVID AND MODERATE TO SEVERE SYMPTOMS

ESSOR is a double-blind, placebo-controlled study of the orally-administered antiviral and inflammation-controlling LAU-7b for the treatment of adults with Long COVID and moderate to severe symptoms.

开始日期2023-11-20

申办/合作机构

Laurent Pharmaceuticals, Inc.

100 项与芬维A胺相关的临床结果

登录后查看更多信息

100 项与芬维A胺相关的转化医学

登录后查看更多信息

100 项与芬维A胺相关的专利（医药）

登录后查看更多信息

1,041

项与芬维A胺相关的文献（医药）

2023-11-01·Cellular signalling

Fenretinide induces apoptosis and synergises the apoptosis inducing effect of gemcitabine through inhibition of key signalling molecules involved in A549 cell survival in in silico and in vitro analyses

Article

作者: Al-Bustany, Hazem A ; Muhammad, Hawzheen A ; Chawsheen, Mahmoud A ; Dash, Phil R

Fenretinide is a synthetic retinoid compound, which induces apoptosis via generating reactive oxygen species (ROS) and modulating PI3K/Akt/mTOR signalling pathway. We hypothesise that fenretinide's mechanism of action in triggering apoptosis may involve other targets, beside mTOR signalling pathway and it may augment apoptosis inducing effects of chemotherapeutic drugs in lung cancer. Time-lapse microscopy and Western blotting were used to evaluate apoptosis and apoptotic marker cleaved-Caspase 3 in A549 cells. Relative levels of protein phosphorylation and ROS were quantified by Human Phospho-Kinase Array Kit and CellROX® Green Reagent, respectively. Docking and simulation analyses of proteins and fenretinide interactions were identified and visualised by Discovery Studio Visualizer and AutoDock Vina software. Our results showed that fenretinide induced apoptosis in a dose dependant manner and combinations of fenretinide (5 μg/mL) and gemcitabine (1, 2, 4, 8 and 16 μg/mL) synergistically enhanced apoptosis in A549 cells. Fenretinide caused significant increase of cleaved-Caspase 3, de-phosphorylated p-S473 of Akt and failed to inhibit mTORC1 downstream targets. In silico results revealed that Akt required the lowest energy (-10.2 kcal/mol) to interact with fenretinide in comparison with other proteins. In conclusion, Akt may be exploited as a good target for induction of apoptosis in A549 cells and fenretinide has great potentials to fulfil this task. The mechanism by which fenretinide boosts the apoptosis inducing effects of gemcitabine, which is likely expected to be via inhibiting mTORC2 downstream targets. However, docking investigation revealed that fenretinide lacks specificity as it may also interact with several secondary targets beside Akt.

2023-10-01·Aquatic toxicology (Amsterdam, Netherlands)

Triphenyl phosphate-induced pericardial edema in zebrafish embryos is reversible following depuration in clean water

Article

作者: Ha, Megan ; Zhang, Sharon ; Volz, David C ; Avila-Barnard, Sarah ; Hoang, John ; Wiegand, Jenna ; Stapleton, Heather M ; Nemarugommula, Charvita

Triphenyl phosphate (TPHP) - a widely used organophosphate-based flame retardant - blocks cardiac looping during zebrafish development in a concentration-dependent manner, a phenotype that is dependent on disruption of embryonic osmoregulation and pericardial edema formation. However, it's currently unclear whether (1) TPHP-induced effects on osmoregulation are driven by direct TPHP-induced injury to the embryonic epidermis and (2) whether TPHP-induced pericardial edema is reversible or irreversible following cessation of exposure. Therefore, the objectives of this study were to determine whether TPHP-induced pericardial edema is reversible and whether TPHP causes injury to the embryonic epidermis by quantifying the number of DAPI-positive epidermal cells and analyzing the morphology of the yolk sac epithelium using scanning electron microscopy. First, we found that exposure to 5 μM TPHP from 24-72 h post-fertilization (hpf) did not increase prolactin - a hormone that regulates ions and water levels - in embryonic zebrafish, whereas high ionic strength exposure media was associated with elevated levels of prolactin. Second, we found that exposure to 5 μM TPHP from 24-72 hpf did not decrease DAPI-positive epidermal cells within the embryonic epithelium, and that co-exposure with 2.14 μM fenretinide - a synthetic retinoid that promotes epithelial wound repair - from 24-72 hpf did not mitigate the prevalence of TPHP-induced epidermal folds within the yolk sac epithelium when embryos were exposed within high ionic strength exposure media. Finally, we found that the pericardial area and body length of embryos exposed to 5 μM TPHP from 24-72 hpf were similar to vehicle-treated embryos at 120 hpf following transfer to clean water and depuration of TPHP from 72-120 hpf. Overall, our findings suggest that (1) the ionic strength of exposure media may influence the baseline physiology of zebrafish embryos; (2) TPHP does not cause direct injury to the embryonic epidermis; and (3) TPHP-induced effects on pericardial area and body length are reversible 48 h after transferring embryos to clean water.

2023-09-11·Angewandte Chemie (International ed. in English)

A Modular Approach for the Synthesis of Natural and Artificial Terpenoids

Article

作者: Ma, Shengming ; Wang, Weiyi ; Qian, Hui ; Huang, Dongyu ; Yu, Yibo

Abstract:

Many terpenoids with isoprene unit(s) demonstrating critical biological activities have been isolated and characterized. In this study, we have developed a robust chem‐stamp strategy for the construction of the key isoprene unit, which consists of two steps: one‐carbon extension of aldehydes to the alkenyl boronates by the boron‐Wittig reaction and the rhodium‐catalyzed reaction of alkenyl boronates with 2,3‐allenols to yield enals. This chem‐stamp could readily be applied repeatedly and separately, enabling the modular concise synthesis of many natural and pharmaceutically active terpenoids, including retinal, β‐carotene, vitamin A, tretinoin, fenretinide, acitretin, ALRT1550, nigerapyrone C, peretinoin, and lycopene. Owing to the diversified availability of the starting materials, aldehydes and 2,3‐allenols, creation of new non‐natural terpenoids has been realized from four dimensions: the number of isoprene units, the side chain, and the two terminal groups.

项与芬维A胺相关的新闻（医药）

2024-06-04

·PRNewswire

SciTech Development Raises Additional $3.2M to Expand Clinical Trials for Cancer

SciTech accelerates its mission to bring ST-001 to cancer patients. GROSSE POINTE FARMS, Mich., June 4, 2024 /PRNewswire/ -- SciTech Development, a clinical-stage, specialty oncology pharmaceutical company, today announced it has closed an additional $3.2 million in funding to continue the active enrollment and dosing of patients in its ongoing clinical trial for T-cell non-Hodgkin lymphoma (T-NHL). This new funding brings SciTech's total raised to over $12 million. SciTech's financing was led by Storm Lake Capital and Pointe Angels, alongside new and existing accredited investors. Proceeds from the financing will be used to advance the company's Phase 1b clinical trials of ST-001 for T-NHL and subsequent clinical trials for small cell lung cancer. "On behalf of Storm Lake Capital, we are thrilled with the initial clinical progress made by SciTech Development and pleased to further support the company through additional investment in its latest convertible note round." said Todd Carlson, Partner, Storm Lake Capital. "As early supporters, we have closely monitored SciTech's advancements, noting its adept handling of challenges and disciplined resource management. We value the management team's integrity and look forward to their continued success." SciTech's T-NHL trial began with the first patient dosed in late 2023 and is being conducted at six (6) prestigious cancer institutions located across the United States in PA, NY, TX, MI, and CA, with additional sites being added. Patient enrollment is now open. Trial information, including criteria and site locations, can be found at ClinicalTrials.gov with the identifier NCT04234048. SciTech anticipates starting a second Phase 1b small cell lung cancer (SCLC) trial to run concurrently with the T-cell lymphoma trial. "SciTech has achieved yet another milestone of having oversubscribed its second Convertible Note Round (CNR) of financing. This is a perfect reflection of the progress that has been made by our dedicated team. Our multicenter clinical trial is to reconfirm the safety and efficacy of the active drug, fenretinide, utilizing SciTech's novel nanoparticle delivery platform." said Earle Holsapple, CEO of SciTech. "We have opened a third CNR to continue advancing the Phase 1b studies for T-NHL and small cell lung cancer. In parallel, the company will launch a Series A capital raise to fund the completion of both trials and file for commercial approval with the FDA. We are confident that the drug's potential will soon be realized." ST-001 is SciTech's patented lead drug product, formulated with the active drug fenretinide (a synthetic retinoid derivative) plus specific phospholipids in a nanoparticalized delivery platform (SDP). ST-001 has achieved a breakthrough in solving the bioavailability issues of fenretinide without system-related toxicities, which allows the drug to reach and kill cancer cells. The FDA has granted ST-001 an Orphan Drug Designation, allowing 7 years of market exclusivity once approved. T-cell lymphoma, a rare disease, is being utilized as the initial gateway indication for ST-001 as the company plans to establish a foothold in other cancer indications. Previous studies with fenretinide have shown promise in at least 15+ other types of cancers, such as lung, breast, ovarian, cervical, pancreatic, leukemia, colo-rectal, head & neck, and brain cancers. These additional indications, plus the potential to add ST-001 as combination therapy, may add significant value to address the unmet clinical needs in oncology. About SciTech Development SciTech Development is a clinical-stage, specialty oncology pharmaceutical company that is revolutionizing how safe and promising yet challenged drugs can be delivered to kill cancer. With innovative science and advanced nanotechnology, SciTech has developed ST-001 nanoFenretinide, a patented formulation that is currently in clinical trials for T-cell lymphomas (a form of non-Hodgkin lymphoma). ST-001 has been granted Orphan Drug Designation by the FDA, which allows 7 years of market exclusivity once approved. In addition, SciTech's nanoparticle drug delivery platform (SDP) maximizes the bioavailability of water-insoluble therapeutics and can potentially develop new drugs or improve other similarly challenged drugs. To learn more about SciTech, the science, and the team, please visit . Contact: SciTech Development: Investor Relations David Schaffer [email protected] Safe Harbor and Forward-Looking Statement: This document contains certain forward-looking statements that involve risks and uncertainties. Such forward-looking statements include statements regarding attempts to identify new products, services, or strategic opportunities, which may include a strategic transaction, plans regarding partnering activities, service pricing, or financial forecasts. Such statements are only predictions, and the Company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include the risk that the Company may not be able to identify acceptable strategic opportunities or conclude any identified strategic transaction, the risk that products or services that appeared promising in early use do not demonstrate the same utility in larger-scale uses or trials, the risks associated with the Company's reliance on outside financing to meet its capital requirements, and the risks associated with the Company's reliance on forward-looking contracts. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underly the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include but are not limited to, the effect of government regulation, political, environmental, competitive, and/or other material risks. SOURCE SciTech Development

临床1期孤儿药临床申请

2023-12-20

·PRNewswire

SciTech Development Announces First Patient Dosed in Phase 1 Clinical Trial of ST-001

This study is designed to evaluate ST-001 for the treatment of T-cell non-Hodgkin's lymphoma (NHL). GROSSE POINTE, Mich., Dec. 20, 2023 /PRNewswire/ -- SciTech Development ("SciTech" or the "Company"), a clinical-stage pharmaceutical company with a novel and patented drug delivery platform, today announced that the company has dosed the first patient in its Phase 1 clinical trial with lead cancer drug candidate, ST-001 nanoFenretinide. ------------------------ Join us here to learn more about the Company and our science: ------------------------ "There have been relatively few new cancer breakthroughs for T-cell lymphoma in several years, so we are excited to announce this milestone for patients suffering from this rare disease." said Earle Holsapple, SciTech's President, and CEO. "Our scientific team has worked extremely hard to bring this new drug to the people that need it most. We currently have four active trial sites with world-renowned medical institutions in New York, California, Pennsylvania, and Michigan, with more sites coming onboard in early 2024 as the trials expand. SciTech is proud to be on the forefront of helping cancer patients and we thank everyone who has supported our journey." The active drug fenretinide has been clinically tested and deemed safe in over 3,000+ patients in previous clinical trials. However, due to bioavailability issues of past fenretinide formulations, high concentrations of the drug could not reach and kill the target cancer cells. SciTech led the effort to find the solution with its patented methods for phospholipids and nanoparticalization to enhance fenretinide's bioavailability, thus developing ST-001 nanoFenretinide. SciTech's Phase 1 clinical trials are targeting patients with T-cell non-Hodgkin's lymphoma, including Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides, Sézary Syndrome, and non-Cutaneous T-cell Lymphoma subtypes. The initial study will determine the Maximum Tolerated Dose (MTD) of ST-001 nanoFenretinide (IV infusion) in patients with CTCL and other T-cell non-Hodgkin's lymphoma. For more detailed trial information, please visit ClinicalTrials.gov; Identifier: NCT04234048. About SciTech Development SciTech Development, LLC is a clinical-stage pharmaceutical company that has developed a patented nanoparticle drug delivery platform (SDP) that maximizes the bioavailability of water-insoluble therapeutics. SciTech's lead drug candidate, ST-001 nanoFenretinide, combines SDP and the drug fenretinide as a broadly applicable anticancer drug. For more information about the Company, please visit: Contact Information: David Schaffer Director; Business Development and Investor Relations [email protected] Safe Harbor – Forward-Looking Statement: This document contains certain forward-looking statements that involve risks and uncertainties. Such forward-looking statements include statements regarding attempts to identify new products, services or strategic opportunities which may include a strategic transaction, plans regarding partnering activities, service pricing or financial forecasts. Such statements are only predictions, and the Company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include the risk that the Company may not be able to identify acceptable strategic opportunities or conclude any identified strategic transaction, the risk that products or services that appeared promising in early use do not demonstrate the same utility in larger-scale uses or trials, the risks associated with the Company's reliance on outside financing to meet its capital requirements, and the risks associated with the Company's reliance on forward-looking contracts. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underly the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, political, environmental, competitive, and/or other material risks. SOURCE SciTech Development

临床1期

2023-10-26

·PRNewswire

SciTech Development Announces The Formation of a Distinguished Medical Advisory Board With Top Oncology Specialists

GROSSE POINTE FARMS, Mich., Oct. 26, 2023 /PRNewswire/ -- SciTech Development, LLC, today announced the formation of a distinguished and independent medical advisory board (MAB) comprised of key opinion leaders and world-renowned experts in T-Cell Lymphomas and hematological malignancies. The board will provide strategic and clinical advice for SciTech's outreach and education initiatives within the oncology community. Continue Reading SciTech Medical Advisory Board "SciTech is excited and incredibly proud that this world-class group of medical experts will assist us with innovative insights that enable us to bring ST-001 to patients who have limited options in their cancer treatments," said President and Managing Partner Earle Holsapple. "The clarity they bring in understanding the clinical needs of patients will serve to guide us through the commencement of our phase 1 clinical trial and through our subsequent expedited clinical program." The three medical advisors appointed to the board are Madeleine Duvic, M.D., Larisa Geskin, M.D., and Ajay Gopal, M.D. Madeleine Duvic, MD – "The development of ST-100 is exciting because this new drug holds the promise of improved bioavailability, leading to increased efficacy with low toxicity." Dr. Duvic is a Professor of Medicine and Dermatology practices in Houston, Texas, and holds the Blanche Bender Endowed Chair of Research. Her clinical research includes translational/molecular studies leading to improved therapies for cutaneous T-cell lymphomas. She has written over 500 peer-reviewed papers and a book on Retinoids. She participated in the development of topical and oral tazarotene and bexarotene which both received FDA approval. Larisa J. Geskin, MD, FAAD - "I am thrilled to support SciTech's innovative approach to cancer therapeutics. SciTech's patented nanoparticle platform, SDP, enhances the effectiveness and safety of fenretinide, which has shown promise in treating patients with incurable cutaneous lymphomas in preliminary studies. SciTech's flagship product, ST-001, stands out for its ability to deliver therapeutic doses without toxic side effects, greatly benefiting our patients." Dr. Geskin is a Professor of Dermatology (in Medicine, Division of Hematology-Oncology) at Columbia University Medical Center and the Director of the Comprehensive Cutaneous Oncology Center at the Columbia University Department of Dermatology. Dr. Geskin serves as the Immediate Past-President of the International Society for Cutaneous Lymphomas (ISCL), the Secretary-Treasurer of the US Cutaneous Lymphomas Consortium (USCLC), and the Founding Chair of the New York Cutaneous Lymphoma Consortium (NYCLC), among her many other responsibilities. Ajay K. Gopal, MD - "Based on the encouraging preclinical data from a variety of laboratories, our observed tolerability of fenretinide, and the unmet need in a spectrum of malignancies novel formulations such as ST-001 nanoFenretinide are certainly worthy of further investigation." Dr. Gopal received his undergraduate degree from Duke University and his MD from Emory University. He completed his internal medicine training at Duke University School of Medicine and his oncology training at the University of Washington and Fred Hutchinson Cancer Center, where he currently holds an endowed chair and serves as a Professor and Clinical Research Director for Hematologic Malignancies. Dr. Gopal has over 2 decades of experience in the development of novel therapies for lymphoma, as reflected by over 200 publications in the field, including the first translational and clinical trial data evaluating fenretinide in lymphoma. Contact: Earle Holsapple Email: [email protected] About SciTech Development SciTech Development, LLC is a clinical-stage pharmaceutical company that has developed a patented nanoparticle drug delivery platform (SDP) that maximizes the bioavailability of water-insoluble therapeutics. SciTech's lead drug candidate, ST-001 nanoFenretinide, combines SDP and the drug fenretinide as a new drug product with potentially broad effectiveness in many cancers. For more information about the Company, please visit: SOURCE SciTech Development

临床1期高管变更

100 项与芬维A胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04162	芬维A胺	-	DB05076

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新冠肺炎后遗症	临床3期	加拿大	Laurent Pharmaceuticals, Inc.	2023-11-20
新型冠状病毒感染	临床3期	美国	Laurent Pharmaceuticals, Inc.	2020-06-29
乳腺癌	临床3期	意大利	Istituto Europeo di Oncologia SRL	2009-12-01
非肌层浸润性膀胱肿瘤	临床3期	美国	National Cancer Institute	1998-07-30
HR阳性乳腺癌	临床3期	美国	National Cancer Institute	1995-10-01
子宫颈原位癌	临床3期	美国	National Cancer Institute	1993-03-05
宫颈上皮内瘤样病变	临床3期	美国	National Cancer Institute	1993-03-05
癌前状态	临床3期	美国	National Cancer Institute	1993-03-05
囊性纤维化	临床2期	美国	Laurent Pharmaceuticals, Inc.	2018-10-10
囊性纤维化	临床2期	澳大利亚	Laurent Pharmaceuticals, Inc.	2018-10-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03265288 (APPLAUD, Biospace) 人工标引	临床2期	囊性纤维化	166	LAU-7b	壓壓衊積鬱顧觸製廠蓋(選糧遞遞蓋淵憲願築製): difference = 1.23, P-Value = 0.0486	积极	2022-11-03
				Placebo
NCT00546455 (CTgov)	临床2期	肥胖 \| 代谢功能障碍相关的脂肪肝病 \| 胰岛素抵抗 ... 更多	21	Fenretinide (A- Fenretinide)	鬱糧膚遞夢網醖夢衊憲(鏇願鏇網餘選範艱觸繭) = 蓋積衊窪遞艱齋遞網艱遞鏇衊夢夢糧遞獵遞襯 (齋齋獵鬱艱積壓膚醖構, 積齋膚鬱網窪襯鬱膚艱 ~ 觸構築衊醖窪鏇製選製) 更多	-	2021-02-10
				placebo (B-Placebo)	鬱糧膚遞夢網醖夢衊憲(鏇願鏇網餘選範艱觸繭) = 餘鑰築願糧鹹繭獵鹹範遞鏇衊夢夢糧遞獵遞襯 (齋齋獵鬱艱積壓膚醖構, 淵憲鬱觸選鹽壓範構襯 ~ 襯鹽夢糧膚範餘顧窪獵) 更多
NCT00104923 (Pubmed \| Clin Cancer Res) 人工标引	临床1期	血液肿瘤	29	Fenretinide	鏇繭鹹製夢餘鹹鑰獵網(廠醖夢廠憲夢齋鹽鹽鑰) = 壓壓顧鹽繭廠鏇淵艱鹹齋構廠顧獵鬱築鑰獵鏇 (壓醖簾膚餘鹹觸積積夢 )	积极	2017-08-15
				Fenretinide (patients with response-evaluable peripheral T-cell lymphomas)	鬱顧夢襯窪簾艱淵範壓(構構淵醖鹽願齋獵範醖) = 獵鹽齋築夢憲夢鏇夢製蓋繭簾構憲窪遞餘衊構 (鬱簾遞繭餘齋鏇壓顧餘 ) 更多
NCT00288067 (Pubmed \| Br J Haematol) 人工标引	临床1/2期	套细胞淋巴瘤 \| B细胞淋巴瘤	32	fenretinide	製選鑰鬱憲願網壓壓獵(蓋遞繭壓築構鏇鹽製膚) = No dose-limiting toxicities were observed. 齋簾願襯鏇壓衊積獵鹹 (夢壓齋衊網鹽衊窪憲獵 ) 更多	积极	2017-02-01
				fenretinide+rituximab
NCT00080899 (CTgov)	临床2期	复发性前列腺癌 \| 非转移性前列腺癌 \| 前列腺腺癌	23	Fenretinide (N-(4-hydroxyphenyl) retinamide [4-HPR])	餘艱糧觸醖製構淵蓋淵(蓋願艱鑰窪鏇積齋築遞) = 顧範壓觸壓簾餘糧齋夢憲繭鏇糧艱夢淵構窪醖 (醖夢憲淵襯齋廠積遞淵, 夢觸獵遞構構積廠襯鏇 ~ 鏇艱廠築衊選齋範製糧) 更多	-	2015-03-06
NCT00288067 (CTgov)	临床1/2期	复发性滤泡性淋巴瘤 \| 复发性边缘区淋巴瘤 \| 急性淋巴细胞白血病 ... 更多	32	Fenretinide+Rituximab (Fenretinide and Rituximab)	製網憲構鹹遞壓壓膚壓(鏇構齋憲衊網襯壓衊壓) = 積簾衊鏇簾蓋製夢鹽獵鬱顧襯齋壓醖簾簾淵遞 (糧壓獵網淵窪糧鑰構築, 夢蓋製衊膚願鑰鏇選壓 ~ 鑰淵襯鏇積廠齋獵憲淵) 更多	-	2014-10-06
				Fenretinide+Rituximab (Fenretinide and Rituximab (Rituximab Naive))	繭鏇鹽願遞鹹憲淵蓋構(鹽餘範鏇觸選夢壓製簾) = 餘遞憲膚範製衊構膚製獵獵願獵築簾廠鬱餘壓 (簾遞齋範觸獵襯鹹廠鹽, 鹹獵淵網觸願簾鏇遞觸 ~ 選築鑰膚蓋鹹構築簾艱)
NCT00295919 (N2004-04, ASCO2014)	临床1期	神经母细胞瘤	80	4-HPR/LXS oral powder	鏇餘蓋築鑰遞繭廠遞簾(繭鑰繭壓繭鑰衊蓋衊顧) = 艱鑰淵餘顧構築範膚鑰襯餘構簾蓋積醖選蓋壓 (廠糧築築簾積憲獵醖鑰, 1.35 ~ 36.9+) 更多	-	2014-05-20
				Ketoconazole	構獵鬱鑰醖糧繭積選蓋(繭遞觸獵鹹蓋鹹夢醖築) = 鬱憲憲淵糧願鹽餘選餘糧艱範願蓋簾齋鬱廠顧 (鑰艱鹹襯選襯鹹構顧壓, 14.6, 22.1)
PhI-42 (ASCO2012)	临床1期	血液肿瘤	25	Fenretinide (4-HPR) intravenous emulsion	觸襯夢顧鹹憲鏇構顧構(網構簾鹹夢鏇鏇觸選鏇) = Reversible hypertriglyceridemia related to the intralipid vehicle accounted for 6/7 DLTs 糧鬱鹽獵鹽鏇積淵製襯 (繭鹽壓衊鬱觸齋顧獵鹹 )	-	2012-05-20
AACR2012	临床1期	复发性神经母细胞瘤	-	4-HPR/LXS	選憲糧壓糧繭艱蓋廠憲(鏇膚遞顧鹽範齋範鏇鬱) = 顧窪鹽夢糧繭築衊遞鏇製遞齋簾築膚夢襯衊廠 (齋窪製夢膚鬱簾醖窪餘 )	-	2012-04-15